Daqing Oil Field Hospital Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2017
NCT04486430
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Daqing oilfield general hospital | Daqing Oil Field Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

budesonide (rhinocort) (1 trial)

Drugs in Phase 3 Trials (1)

borneol (1 trial)

Drugs in Phase 2 Trials (2)

anlotinib (1 trial)

Nelonemdaz (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Infarction (Phase 2)

Sarcoma (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4